MetaCap

Immunovant (IMVT) vs Vaxcyte (PCVX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Immunovant (IMVT) has outperformed Vaxcyte (PCVX) over the past year, gaining 40.6% versus a gain of 15.9%. Over five years, IMVT leads with a +308.9% price change compared with +178.9% for PCVX. Vaxcyte is the larger company by market cap ($8.77 billion vs $6.57 billion), about 1.3 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

IMVT+40.64%PCVX+15.93%
+104%+45%-15%
Nov 21, 20251 yearNov 20, 2026
IMVT+286.50%PCVX+143.90%
+465%+191%-84%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

IMVT versus PCVX key metrics
MetricIMVTPCVX
Share price$31.77$55.39
Market cap$6.57B$8.77B
1-day change-2.31%-5.09%
YTD return+24.98%+20.05%
1-year return+40.64%+15.93%
5-year return+308.88%+178.90%
EPS (TTM)$-2.56$-8.05
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-505.61M$-766.63M
52-week high$45.42$90.75
52-week low$21.93$42.40
Distance from 52-week high-30.05%-38.96%
Analyst consensusbuynone
Avg. price target upside+53.07%+110.15%
Average volume1.42M2.19M
Shares outstanding206.95M158.30M
Employees315507
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • IMVT has outperformed PCVX by 24.7 percentage points over the past year.

About Immunovant

IMVT stock →

Immunovant, Inc., a clinical-stage immunology company, develops targeted therapies to meet the needs of people with autoimmune diseases. It develops IMVT-1402, a human monoclonal antibody that inhibits neonatal fragment crystallizable receptor for graves' disease, rheumatoid arthritis, sjögren's disease, cutaneous lupus erythematosus disease, myasthenia gravis, and chronic inflammatory demyelinating polyneuropathy.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 315 employees

About Vaxcyte

PCVX stock →

Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 507 employees

IMVT vs PCVX FAQ

Which is bigger, Immunovant or Vaxcyte?

Vaxcyte (PCVX) is larger, with a market capitalization of $8.77B compared with $6.57B for Immunovant (IMVT).

Which stock has performed better over the past year, IMVT or PCVX?

IMVT returned +40.64% over the past 12 months, compared with +15.93% for PCVX (price return, excluding dividends). Past performance does not predict future results.

Are Immunovant and Vaxcyte in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons